The disruption of the microbial community or dysbiosis alters the functional composition, metabolic activity, and local distribution of the microbiota leading the development of acne. The aim of this study is to evaluate the effect of a lotion containing a biotechnological phytocomplex, niacinamide, and succinic acid in the bacterial diversity of subjects with truncal mild-moderate acne and its clinical benefits due to microbiota changes. Open, clinical study in 43 subjects with truncal mild-moderate acne treated with a lotion for 8weeks. Bacterial diversity was analyzed by 16S rRNA gene sequencing of skin samples. Clinical effects were evaluated through IGA acne severity scale, biometric measurements, and safety. After 56 days of product's use, an increase in richness alpha diversity was found (p=0.005), with a decrease in Cutibacterium acnes relative abundance (66.43%vs. 58.11%, p=0.009). The clinical results showed a decrease in IGA score (27.59% decrease; p=0.001), the inflammatory lesions (52.12% decrease, p=0.006) and erythema (18.33% decrease, p=0.007), and desquamation index (63.83% decrease, p=0.02). The responder analysis of the IGA score showed that 60.47% of patients improved by at least one point at day 56. The product was well tolerated along the study. The use of the lotion on acneic skin was effective on rebalancing the microbiota, inhibiting biofilm formation and other virulence factors, reducing erythema and desquamation, and improving acne's severity.